Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARC: Preoperative Chemo-Proton Therapy for Borderline Resectable Pancreatic Cancer
NCT04894643Recruiting
- Sponsor
- MedAustron
- Start
- Sep 2020
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of paclitaxel, gemcitabine and capecitabine in pancreatic cancer (PC), sponsored by MedAustron. Primary endpoints: Toxicity - Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and Perioperative Mortality and Complications. Started Sep 2020; status: recruiting.
02
Drugs
paclitaxelgemcitabinecapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04894643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894643.